TL;DR
Get health and wellness essentials delivered free with Prime
- Fast, free delivery on millions of items
- Prime Video, Amazon Music and more included
- Member-only deals all year
A review in Nutrients examined studies of ergothioneine, an antioxidant found in mushrooms and other foods, and its possible effects on brain health. Some human studies link lower blood levels with poorer cognition, while cell and animal experiments report protective effects; evidence that eating mushrooms or taking the compound prevents neurodegenerative disease remains insufficient.
A review published in the journal Nutrients has examined whether ergothioneine, a naturally occurring antioxidant found in mushrooms and other foods, could help protect the aging brain. The researchers describe suggestive findings in people and more direct results in cell and animal studies, but the evidence does not establish that eating more mushrooms prevents dementia or other neurodegenerative diseases.
Researchers at the University of Rzeszow in Poland reviewed research on ergothioneine, or ET, and its possible effects on memory, inflammation and the survival of nerve cells. Their review brings together observational studies, laboratory experiments and a small number of human trials. It is a review of existing research, not a new clinical trial testing whether mushroom consumption prevents brain disease.
Several observational studies found that people with lower circulating ET levels tended to have poorer cognitive outcomes. In one study of 470 people without cognitive impairment at baseline, lower ET was associated with faster declines in global cognition and in measures of attention, memory, movement and language. Other studies reported lower blood levels among people with mild cognitive impairment or Parkinson’s disease, and an association between lower ET and a greater likelihood of mild cognitive impairment progressing to Alzheimer’s disease.
These findings do not establish cause and effect. The review notes that low ET could contribute to vulnerability, but it could also reflect changes related to illness or greater antioxidant use during oxidative stress. Findings are not consistent across studies: one study linked higher serum ET with increased Alzheimer’s risk. Results from laboratory and animal research are also not direct evidence of benefit from food. Some cell experiments used concentrations unlikely to be reached in people, and animal studies often used doses above typical dietary intake.
What the Findings Mean for Diet
The findings make ET a subject for further research, but they do not yet support a specific dietary prescription. Mushrooms contain ET, yet the review does not show that eating a larger quantity changes blood levels enough to protect cognition, nor that a mushroom-rich diet prevents Alzheimer’s or Parkinson’s disease. The health effects of whole foods also cannot be inferred from experiments using purified ET or extracts.
The question matters because neurodegenerative diseases can impair health, independence and quality of life, and the review notes that there are currently no cures for these conditions. An accessible food-based way to reduce risk would be relevant to many readers. For now, the research supports scientific interest rather than a proven prevention strategy. People should not treat mushrooms or ET supplements as a substitute for medical care or as a guarantee of brain protection.
Products Worth Considering
Blueair Blue Pure 511i Max Smart Air Purifier
Fitbit Sense 2 Health and Fitness Smartwatch, Shadow Grey/Graphite
Garmin Forerunner 570 GPS Running Smartwatch, 42 mm, Raspberry, with P-Bank Bundle
As an affiliate, we earn on qualifying purchases.
From Antioxidant Theory to Trials
Oxidative stress—an imbalance involving reactive molecules that can damage cells—is associated with neurodegenerative disease and may contribute to it. Antioxidants have therefore been studied as possible protective agents. ET is a sulfur-containing antioxidant present in mushrooms and other foods. Earlier work suggested that insufficient dietary ET might contribute to neurodegeneration, but the review says that hypothesis remains unproven.
In cell studies, ET reduced oxidative stress and protected some brain-related cells from damage. In animal models of Alzheimer’s and Parkinson’s disease, it was associated with fewer behavioral or cognitive deficits. Researchers have also proposed other possible actions, including activating the body’s antioxidant response and reducing inflammation. These mechanisms remain research findings, not proof of clinical protection in humans.
Human evidence is limited and mixed. A trial lasting up to 35 days found downward trends in some blood and urine markers of inflammation and oxidative damage, but those changes were not statistically significant. Other short trials reported improvements in subjective sleep or memory measures in particular groups. A 12-week trial of mushroom-extract tablets reported improved verbal memory, but other compounds in the extract could have contributed, so the result cannot be attributed to ET alone.
“Dietary ET deficiency may contribute to neurodegeneration, a hypothesis that remains unproven.”
— The University of Rzeszow researchers, as summarized in the review
Key Questions Still Open
It remains unclear whether low ET levels are a cause, consequence or marker of cognitive decline. Studies report associations, but those cannot show that raising ET would prevent disease. The conflicting finding linking higher serum ET with increased Alzheimer’s risk adds to the uncertainty.
The human trials described in the review were short and assessed outcomes such as sleep complaints, subjective memory or selected biomarkers. They do not show that ET prevents dementia or slows neurodegenerative disease over the long term. It is also not clear how much ET people absorb from ordinary servings of mushrooms, what intake would be needed for a measurable effect, or whether supplements provide the same effects as food. No specific serving recommendation or proven preventive dose is established by the review.
Evidence Needed Before Advice Changes
The next step is stronger human research that follows participants for longer and tests clinically meaningful cognitive or disease outcomes. Trials would need to clarify dose, safety and whether any observed effect comes from ET itself, whole mushrooms or other compounds in extracts. Researchers would also need to account for the possibility that blood ET levels reflect existing health changes rather than causing them.
Until that evidence is available, the review supports continued investigation—not a claim that mushrooms protect against dementia. Readers considering ET supplements for a health concern should discuss that decision with a qualified health professional, particularly because the reviewed studies do not establish long-term preventive benefit.
Key Questions
Does this review show that mushrooms prevent Alzheimer’s disease?
No. It reviews suggestive associations and experimental findings, but does not establish that eating mushrooms prevents Alzheimer’s disease.
What is ergothioneine?
Ergothioneine (ET) is a naturally occurring antioxidant found in mushrooms and other foods. Researchers are studying its possible effects on oxidative stress, inflammation and brain health.
Do lower blood levels of ET cause cognitive decline?
That is not known. Observational studies report links between lower ET and poorer outcomes, but they cannot establish whether low levels contribute to decline or result from other changes associated with illness.
Have ET supplements been proven to protect memory?
No. Some short human trials reported changes in sleep or memory measures, but the reviewed evidence does not show that ET supplements prevent dementia or provide long-term brain protection.
Source: news-medical.net
